Braveheart Bio, Inc.

BRVE

Healthcare Biotechnology

EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

19.62 0.88 −4.29%
Market cap
$1.8B
P/E
n/m
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
−28.7%
Net debt / EBITDA
1.3×
Payout ratio
—

What it owns vs. what it owes Q3 FY2026, 30 September 2026

It holds $503.4M more in cash and investments than it owes in debt. Shareholders’ equity is 97% of the balance sheet. What is a balance sheet?

30 September 2026 · total $514.5M

Owns

$628.0KLong-term assets
$10.3MOther short-term assets
$503.5MCash & all investments

Funded by

$497.6MShareholders’ equity
$16.7MOther liabilities
$100.0KDebt

Debt is 0.0% of the total; shareholders’ equity 96.7%.

Older periods Dec '25 Mar '26 Jun '26 Sep '26
Total current assets
89.28 81.07 123.45 359.57
Total non-current assets
0.07 0.81 3.51 154.88
Total Assets
89.35 81.88 126.96 514.45
Total current liabilities
5.24 10.00 9.06 16.67
Total non-current liabilities
149.98 150.27 213.80 0.18
Total liabilities
155.22 160.27 222.86 16.85
Common Equity (Total)
(65.87) (78.39) (95.91) 497.60
Shareholders Equity (Total)
(65.87) (78.39) (95.91) 497.60
Total Debt
— 0.29 0.20 0.10

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated 12 Nov 2026